Legend Biotech is building a new $150 million manufacturing plant, with its partner Johnson & Johnson, with the goal of ...

Legend Biotech’s financial performance has been strong, with Carvykti sales showing significant growth. According to InvestingPro analysis, the company maintains a healthy financial position ...

Morgan Stanley analyst Vikram Purohit lowered the firm’s price target on Legend Biotech (LEGN) to $80 from $82 and keeps an Overweight rating ...

Arcellx's innovative cell therapy platform shows promising potential in treating multiple myeloma, a significant unmet ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...

Johnson & Johnson and Legend Biotech will arrive at next week's ASCO congress with a new EU approval for multiple myeloma CAR-T Carvykti. The European Commission has cleared Carvykti ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Johnson & Johnson and Legend Biotech’s BCMA-targeted CAR-T therapy Carvykti has been approved by the FDA to treat patients with multiple myeloma after at least one prior therapy. The decision ...

The company’s flagship product, Carvykti, a CAR-T therapy for multiple myeloma, has demonstrated strong efficacy and is driving the company’s growth prospects. This comprehensive analysis examines ...

The firms expect that by expanding manufacturing capacity they can double the sales volume of Carvykti from 10,000 doses in 2025 to 20,000 doses in 2027.